Formulation and In-Vitro Evaluation of Niosomal drug Delivery in Cancer Chemotherapy by Kalra, Naresh & Jeyabalan, G.
   
               
 *Corresponding Author: Naresh Kalra, Department of Pharmaceutical Sciences, Sunrise Pharmacy College, SRU, Alwar, Rajasthan, 
India E-Mail: neshu07@gmail.com                                                                                                                                                         29                                                                                                                             
    
 
Indian J. Pharm. Biol. Res. 2017; 5(4):29-33
                                                          
 
Research Article 
Formulation and In-Vitro Evaluation of Niosomal drug Delivery in Cancer 
Chemotherapy 
 
Naresh Kalra1*, G Jeyabalan2 
1Department of Pharmaceutical sciences, Sunrise Pharmacy College, SRU, Alwar, Rajasthan, India  
2Department of Pharmacy, Alwar Pharmacy College, Alwar, Rajasthan India 
 
ARTICLE INFO: 
Article history: 
Received: 15 September 2018 
Received in revised form: 
15 November 2017 
Accepted: 20 November 2017 
Available online: 31December 2017 
Keywords: 
Niosomes,  
Ethanol injection method, 
 In-vitro release 
Span 20. 
 
 
ABSTRACT 
Drug delivery systems are defined as formulations aim for transportation of a drug to the 
desired area of action within the body. The aim of the study was to investigate the feasibility 
of using Niosomes as a drug delivery system for Cisplatin By entrapment of drug in 
Niosomes, dose also could be reduced. Niosomes were prepared by Ethanol injection method 
using cholesterol and Surfactant. Particle size, zeta potential, entrapment efficiency and in 
vitro drug release studies were performed. The targeted niosome delivery system is composed 
of drug, surfactant and cholesterol. With regard to the influence of formulation variables on 
the percent drug loading (PDL), different compositions with varying ratios of surfactant and 
cholesterol were studied. In –Vitro drug release mechanism was studied for 24 hours.  
 
  Introduction
Niosomes are non-ionic surfactant based Multilamellar or 
unilamellar vesicles in which an aqueous solution of solute(s) 
in entirely enclosed by membrane resulted from the 
organization of surfactant macro-molecules as bilayer. The 
potential for Niosomes in cancer drug delivery is infinite with 
novel applications constantly being explored [1].Niosomes is 
a novel drug delivery system in which drug is encapsulated in 
vesicles. Niosomes proved to be a promising drug carrier and 
has potential to reduce the side effects of drugs and increased 
therapeutic effectiveness in various diseases. They improve 
the therapeutic performance of the drug by protecting it from 
the biological environment and restricting effects to target 
cells, thereby reducing the clearance of the drug. The 
Niosomal dispersions in an aqueous phase can be emulsified 
in a non-aqueous phase to control the release rate of the drug 
and administer normal vesicles in external non-aqueous phase 
[2]. 
Cisplatin is a chemotherapy drug. It is used to treat various 
types of cancers, including sarcomas, some carcinomas (e.g. 
small cell lung cancer, and ovarian cancer), lymphomas, and 
germ cell tumors. It was the first member of a class of 
platinum containing anti-cancer drugs, which now also 
includes carboplatin and oxaliplatin. Cisplatin is administered 
intravenously as short-term infusion in physiological saline 
for treatment of solid malignancies. In niosomes the vesicles 
forming amphiphilic are a nonionic surfactant such as span 60 
which is usually stabilized by addition of cholesterol. 
Cholesterol is the membrane stabilizing agent & essential 
component in Niosomal formulation.  
Materials and Methods 
Materials 
Cisplatin, Cholesterol, Span 20  were procured from S.D Fine 
Chem Ltd. Boisar, Chloroform from Qualigens Chem Ltd, 
Biosar, Dialysis bag(M.Wt: 12,000-14000)  from Himedia 
Mumbai, Methanol(HPLC grade) Procured from Merck, 
India. All chemicals used were analytical grade. 
 Method 
In this method ethanol was used as an organic solution for 
dissolving the cholesterol, span& Tween. It has been reported 
that small unilamellar vesicles can be prepared by this 
method. This method has been reported as one of the 
alternatives used for the preparation of small unilamellar 
vesicles (SUVs) without Sonication. In this method, an 
ethanol solution of surfactant is injected rapidly through a fine 
needle into excess of saline or other aqueous medium [3]. 
Vaporization of ethanol leads to the formation of vesicles. 
Niosomes were prepared by ethanol injection method. 
Cholesterol and surfactant were dissolved in 8ml diethyl ether 
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mixed with 2ml methanol containing weighed quantity of 
Drug. The resulting solution was slowly injected using a 
micro syringe at a rate of 1ml/min. into 10 ml hydrating 
solution phosphate buffer (PH7.4) the solution was injected 
slowly into the aqueous phase, the differences in temperature 
between phase cause rapid vaporization and formation of 
Niosomes[4,5]. Different batches of Niosomes were prepared 
in order to select an optimized formula as per general method 
described above and proportion of surfactant and cholesterol 
for the preparations of Niosomes. The ratios of the 
formulations were of cholesterol: surfactants were given in 
table no.1.  
Table 1: Composition of Surfactant and Cholesterol for Preparation of Niosomes 
Formulation Code Surfactant used Surfactant: Cholesterol (micro molar ratio)Diethyl ether (ml) Methanol  
(ml) 
CP1 Span20 150:100 8 2 
CP2 Span20 150:150 8 2 
CP3 Span20 200:150 8 2 
CP4 Span20 250:150 8 2 
CP5 Span20 200:200 8 2 
CP6 Span20 250:200 8 2 
CP7 Span20 250:250 8 2 
CP8 Span20 300:250 8 2 
CP9 Span20 350:250 8 2 
 
Evaluation of anticancer Niosomes formulation 
Removal of unentrapped drug from Niosomes 
The unentrapped drug from niosomes was removed by 
dialysis technique for 24 hours. The various factors like lipid 
concentration, drug to lipid ratio, cholesterol content will 
change the entrapment efficiency. 
Percentage drug Entrapment efficiency   
Cisplatin was incorporated into niosomes by ethanol injection 
method by using phosphate buffer saline pH7.4 as hydrating 
medium that ensured better drug stability. Niosomes 
consisting of different ratio of surfactant and cholesterol 
indicated those variables on the degree of entrapment. 
After the removal of unentrapped drug by dialysis method, 
the entrapment of all the formulation was studied. The 
various factors like lipid concentration, drug to lipid ratio, 
cholesterol content will change the entrapment efficiency. 
The decrease amount of cholesterol will decrease the 
entrapment efficiency of Cisplatin citrate. The lipophilicity 
also influences the entrapment of drug. The results are shown 
in the following Table no. 2.  
Vesicles diameter vesicles diameter measured by using 
optical microscope with a calibrated eyepiece micrometer. 
The vesicles size of niosome is measured individually for all 
batches and its mean value is calculated [6-,8]. 
 
Zeta potential  
Zeta potential of a niosome is commonly used to characterize the 
surface charge property of niosomes. It reflects the electrical 
potential of particles and is influenced by the composition of the 
particle and the medium in which it is dispersed. The zeta potential 
of the optimized formulation was found to be -30.3mv.  The 
obtained result of the zeta potential of prepared formulation remains 
suspended and so were found to be stable and particles being 
suspended. The formulation was found to be effective for parenteral 
administration in the treatment of cancer [9-,12]. The result of zeta 
potential shows that niosomes can be suspended in water well and 
this is important for their storage and administration. Polydispersity 
index an estimate of the width of distribution, indicates the size 
heterogeneity [13-15]. 
In Vitro Drug release study of Cisplatin Niosomes 
In Vitro release was found to be biphasic as the release was 
controlled by dialysis membrane and lipid bilayer. Incorporation of 
cholesterol affected the release rate of encapsulated drug. Based on 
the entrapment efficiency of the formulation were subjected to in 
vitro drug release studies. The media used for this study is 
phosphate buffer (pH7.4). The temperature of the receptor medium 
is maintained at 37±10oC. Aliquots of 5ml sample were withdrawn 
same volume of the medium was replaced. The collected samples 
were analyzed at UV spectrophotometer.  
 
Table 2: Percentage drug Entrapment Efficiency Cisplatin Niosomes 
 
Sr.  
No. 
Batch  
Code 
Surfactant  
used 
Surfactant:Cholestrol  
(micromolar ratio) 
%  of drug  
dialyzed 
Entrapment  
efficiency (%) 
1. CP1 Span20 150:100 17.92 82.18±0.42 
2. CP2 Span20 150:150 19.71 80.29±0.79 
3. CP3 Span20 200:150 15.35 84.65±0.31 
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4. CP4 Span20 250:150 24.54 75.46±0.59 
5. CP5 Span20 200:200 7.16 92.21±0.78 
6. CP6 Span20 250:200 27.46 72.54±0.72 
7. CP7 Span20 250:250 32.85 67.15±0.24 
8. CP8 Span20 300:250 29.59 70.41±0.67 
9. CP9 Span20 350:250 35.4 64.60±0.42 
 
 
 
 
 
Figure No. 1: Zeta Size of Cisplatin Niosomes vesicles 
 
 
 
 
Figure No. 2 Zeta Potential of Cisplatin Niosomes vesicles  
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Figure No. 3. Comparative In Vitro Release study of Cisplatin Niosomal Formulation (CP1-CP9) 
 
Conclusion 
 
Niosomes of Cisplatin was prepared successfully by ethanol 
injection method. Relationship between surfactant type and 
characterization parameters of niosomes was established. In 
present study, the finding revealed that the process parameters 
critically affect the formulation of niosomes with regards to 
drug entrapment and need to be carefully controlled. The 
results of this study showed that cholesterol content and the 
type of surfactant altered the entrapment efficiency and drug 
release. 
Entrapment efficiency and in vitro studies showed that 
formulation CP5 might be more beneficial for drug delivery 
among other formulations. The optimized formulation was 
showing small vesicles size, high percentage of entrapment 
with the desired sustained release of Cisplatin.  In Vitro release 
from Niosomal formulations showed extended release of drug 
for 24hours. The formulation Cisplatin having entrapment 
efficiency of 92.21% and In vitro release after 24 hours for the 
best formulation was 93.9%.  
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